Request Demo

Last update 08 May 2025

Demoxytocin

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Demoxytocin (INN), Desaminooxytocin

+ [4]

Target

OXTR

Action

agonists

Mechanism

OXTR agonists(Oxytocin receptor agonists)

Therapeutic Areas

Other Diseases

Active Indication

Induced Abortion

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC43H65N11O12S2

InChIKeyGTYWGUNQAMYZPF-QPLNMOKZSA-N

CAS Registry113-78-0

Sequence Code 10029901

100 Clinical Results associated with Demoxytocin

100 Translational Medicine associated with Demoxytocin

100 Patents (Medical) associated with Demoxytocin

273

Literatures (Medical) associated with Demoxytocin

08 Feb 2024·Journal of Medicinal ChemistryQ1 · MEDICINE

Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers

Q1 · MEDICINE

Review

Author: Muttenthaler, Markus ; Sanchez de la Rosa, Cristina ; Kalaba, Predrag ; Möller, Andreas ; Alewood, Paul F.

Breast cancer is a leading cause of death in women, and its management highly depends on early disease diagnosis and monitoring. This remains challenging due to breast cancer's heterogeneity and a scarcity of specific biomarkers that could predict responses to therapy and enable personalized treatment. This Perspective describes the diagnostic landscape for breast cancer management, molecular strategies targeting receptors overexpressed in tumors, the theranostic potential of the oxytocin receptor (OTR) as an emerging breast cancer target, and the development of OTR-specific optical and nuclear tracers to study, visualize, and treat tumors. A special focus is on the chemistry and pharmacology underpinning OTR tracer development, preclinical in vitro and in vivo studies, challenges, and future directions. The use of peptide-based tracers targeting upregulated receptors in cancer is a highly promising strategy complementing current diagnostics and therapies and providing new opportunities to improve cancer management and patient survival.

01 Dec 2022·Pharmaceutical Chemistry Journal

Preparative Solid-Phase Method of S–S Bond Closure in Desamino-Analogs of Neurohypophyseal Hormones

Author: Sidorova, M. V. ; Ovchinnikov, M. V. ; Molokoedov, A. S. ; Avdeev, D. V.

An ew high-tech methodol. for the synthesis of desamino-analogs of neurohypophyseal hormones has been developed.The procedure is a completely solid-phase variant including the disulfide bond closure step.All crude products are obtained with 92% purity and contain minimal impurities, which is attractive for large-scale manufacturing of S-S peptides.

01 Mar 2022·Journal of Peptide ScienceQ4 · BIOLOGY

Clearance of oxytocin and its potentially enzyme resistant analogues in the OXT‐receptor compartment of the potassium depolarized rat myometrium

Q4 · BIOLOGY

Article

Author: Jutz, Guido ; Pliska, Vladimir

The time–response behaviour of a group of oxytocin analogues structurally modified on potential sites of oxytocin splitting by tissue inactivation enzymes (“enzyme probes”) was investigated ex vivo on the potassium depolarized rat myometrium (at 30°C) and compared with the data obtained in the in vivo experiments. The modified oil‐immersion method by Kalsner and Nickerson was used to record time profiles after cessation of a steady state myometrium contraction triggered by analogues in a high potassium tissue medium. An exchange of the aqueous medium for mineral oil enables to suppress return diffusion of the peptide and to record its irreversible clearance near the corresponding receptor compartment. Response records were analysed by a nonlinear numeric procedure based on combination of steady state and kinetic terms that allows concomitant estimations of affinities from time–response measurements, in the given case for analogues on depolarized myometrium. Potential inactivation‐sensitive sites in the oxytocin chain are the Ν‐terminal peptide bond Cys1‐Tyr2 (aminopeptidase splitting), the intramolecular disulphide bridge (reduction and formation of the practically inactive linear peptide) and the C‐terminal Leu8‐GlyNH29 or the Pro7‐Leu8 (postprolin cleaving enzyme) bond, respectively. Clearance rate constants of single peptides in the OXT‐receptor compartment were in an interval of 0.025 to 0.28 min−1. The fragment contribution analysis reveals a significant linear additivity of individual structural changes and thus a predictivity of irreversible inactivation rate in the receptor compartment. The most potent inactivation of oxytocin is associated with aminopeptidase splitting; other enzymes may play some though nondecisive role. Less significant differences within the peptide group were found for rate constants for peptide transport between receptor compartment and its external aqueous medium. Besides rate constants, the evaluation of time–response data yields affinity values of the tested peptides and indicates a 25‐times desensitation of depolarized compared with a native state.

100 Deals associated with Demoxytocin

External Link

KEGG	Wiki	ATC	Drug Bank
D07228	Demoxytocin	H01BB01	DB13798

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Induced Abortion	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis